These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 32873122)

  • 21. Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study.
    Komatsu R; Honda M; Holzgrefe HH; Kubo J; Yamada Y; Isobe T; Kimura K; Itoh T; Tamaoki N; Tabo M
    J Pharmacol Toxicol Methods; 2010; 61(3):271-6. PubMed ID: 20097298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deferasirox does not induce QT/QTc-prolongation in healthy subjects.
    Sechaud R; Dumortier T; Balez S
    Int J Clin Pharmacol Ther; 2009 May; 47(5):321-7. PubMed ID: 19473594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly automated QT measurement techniques in 7 thorough QT studies implemented under ICH E14 guidelines.
    Couderc JP; Garnett C; Li M; Handzel R; McNitt S; Xia X; Polonsky S; Zareba W
    Ann Noninvasive Electrocardiol; 2011 Jan; 16(1):13-24. PubMed ID: 21251129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized study of the effect of gadopiclenol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects.
    Funck-Brentano C; Felices M; Le Fur N; Dubourdieu C; Desché P; Vanhoutte F; Voiriot P
    Br J Clin Pharmacol; 2020 Nov; 86(11):2174-2181. PubMed ID: 32302009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
    German P; Mathias A; Brainard DM; Song Q; Ling J; Kearney BP
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):641-651. PubMed ID: 29058821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults.
    Boni JP; Leister C; Hug B; Burns J; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1433-42. PubMed ID: 22367193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of three fluoroquinolones on QT analysis after standard treatment courses.
    Tsikouris JP; Peeters MJ; Cox CD; Meyerrose GE; Seifert CF
    Ann Noninvasive Electrocardiol; 2006 Jan; 11(1):52-6. PubMed ID: 16472283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of QT prolongation using a novel electrocardiographic analysis algorithm applying intelligent automation: prospective blinded evaluation using the Cardiac Safety Research Consortium electrocardiographic database.
    Green CL; Kligfield P; George S; Gussak I; Vajdic B; Sager P; Krucoff MW
    Am Heart J; 2012 Mar; 163(3):365-71. PubMed ID: 22424006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concentration-effect modeling based on change from baseline to assess the prolonging effect of drugs on QTc together with an estimate of the circadian time course.
    Ferber G; Wang D; Täubel J
    J Clin Pharmacol; 2014 Dec; 54(12):1400-6. PubMed ID: 24935561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.
    Khalilieh SG; Yee KL; Fan L; Liu R; Heber W; Dunzo E; Triantafyllou I; Hussaini A; Iwamoto M
    Clin Drug Investig; 2017 Oct; 37(10):975-984. PubMed ID: 28785879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs.
    Rohatagi S; Carrothers TJ; Kuwabara-Wagg J; Khariton T
    J Clin Pharmacol; 2009 Nov; 49(11):1284-96. PubMed ID: 19734373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing QT interval variability of semiautomated and high-precision ECG methodologies in seven thorough QT studies-implications for the power of studies intended for definitive evaluation of a drug's QT effect.
    Meiser K; Jordaan P; Latypova S; Darpo B
    Ann Noninvasive Electrocardiol; 2017 Jan; 22(1):. PubMed ID: 27995684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Retosiban on Cardiac Repolarization in a Randomized, Placebo- and Positive-controlled, Crossover Thorough QT/QTc Study in Healthy Men and Women.
    Stier B; Fossler M; Liu F; Caltabiano S
    Clin Ther; 2015 Jul; 37(7):1541-54. PubMed ID: 26138866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.
    Wang Z; Xuan F; Lin WH; Troyer MD; Tendolkar A; Cutler DL
    Eur J Clin Pharmacol; 2013 Oct; 69(10):1761-7. PubMed ID: 23857248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of moxifloxacin in canine and non-human primate telemetry assays: Comparison of QTc interval prolongation by timepoint and concentration-QTc analysis.
    Chui RW; Baublits J; Chandra FA; Jones ZW; Engwall MJ; Vargas HM
    Clin Transl Sci; 2021 Nov; 14(6):2379-2390. PubMed ID: 34173339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods.
    Lu J; Li J; Helmlinger G; Al-Huniti N
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):469-482. PubMed ID: 29556866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
    Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
    Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.
    Tatosian DA; Cardillo Marricco N; Glasgow XS; DeGroot B; Dunnington K; George L; Gendrano IN; Johnson-Levonas AO; Swearingen D; Kauh E
    Clin Pharmacol Drug Dev; 2016 Sep; 5(5):383-92. PubMed ID: 27627194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.